Coherus hits FDA hurdles for PD-1 drug, Neulasta biosimilar on-body injector

After a complete response letter and delayed preapproval inspections, the FDA found a fresh problem at a clinical trial site for Coherus’ Junshi Biosciences-partnered toripalimab, Coherus said Monday.